Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
FGFR mutation
i
Other names:
FGFR, Fibroblast Growth Factor Receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related biomarkers:
Expression
Fusion
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
FGFR mutation
Cholangiocarcinoma
FGFR mutation
Cholangiocarcinoma
erdafitinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
erdafitinib
Sensitive
:
C3
ASCO-GI 2023 - 2wk
erdafitinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
erdafitinib
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR mutation
Urothelial Cancer
FGFR mutation
Urothelial Cancer
erdafitinib
Sensitive: A2 - Guideline
erdafitinib
Sensitive
:
A2
erdafitinib
Sensitive: A2 - Guideline
erdafitinib
Sensitive
:
A2
FGFR mutation
Urothelial Cancer
FGFR mutation
Urothelial Cancer
pemigatinib
Sensitive: C2 – Inclusion Criteria
pemigatinib
Sensitive
:
C2
pemigatinib
Sensitive: C2 – Inclusion Criteria
pemigatinib
Sensitive
:
C2
FGFR mutation
Pancreatic Cancer
FGFR mutation
Pancreatic Cancer
pemigatinib
Sensitive: C2 – Inclusion Criteria
pemigatinib
Sensitive
:
C2
pemigatinib
Sensitive: C2 – Inclusion Criteria
pemigatinib
Sensitive
:
C2
FGFR mutation
Urothelial Cancer
FGFR mutation
Urothelial Cancer
erdafitinib + JNJ-63723283
Sensitive: C3 – Early Trials
erdafitinib + JNJ-63723283
Sensitive
:
C3
erdafitinib + JNJ-63723283
Sensitive: C3 – Early Trials
erdafitinib + JNJ-63723283
Sensitive
:
C3
FGFR mutation
Urothelial Cancer
FGFR mutation
Urothelial Cancer
FGFR inhibitor
Sensitive: C3 – Early Trials
FGFR inhibitor
Sensitive
:
C3
FGFR inhibitor
Sensitive: C3 – Early Trials
FGFR inhibitor
Sensitive
:
C3
FGFR mutation
Solid Tumor
FGFR mutation
Solid Tumor
ICP-192
Sensitive: C3 – Early Trials
ICP-192
Sensitive
:
C3
ICP-192
Sensitive: C3 – Early Trials
ICP-192
Sensitive
:
C3
FGFR mutation
Cholangiocarcinoma
FGFR mutation
Cholangiocarcinoma
ponatinib
Sensitive: C3 – Early Trials
ponatinib
Sensitive
:
C3
ponatinib
Sensitive: C3 – Early Trials
ponatinib
Sensitive
:
C3
FGFR mutation
Cholangiocarcinoma
FGFR mutation
Cholangiocarcinoma
pemigatinib
Sensitive: C3 – Early Trials
pemigatinib
Sensitive
:
C3
pemigatinib
Sensitive: C3 – Early Trials
pemigatinib
Sensitive
:
C3
FGFR mutation
Non Small Cell Lung Cancer
FGFR mutation
Non Small Cell Lung Cancer
pemigatinib
Sensitive: C3 – Early Trials
pemigatinib
Sensitive
:
C3
pemigatinib
Sensitive: C3 – Early Trials
pemigatinib
Sensitive
:
C3
FGFR mutation
Astrocytoma
FGFR mutation
Astrocytoma
pemigatinib
Sensitive: C3 – Early Trials
pemigatinib
Sensitive
:
C3
pemigatinib
Sensitive: C3 – Early Trials
pemigatinib
Sensitive
:
C3
FGFR mutation
Uterine Cancer
FGFR mutation
Uterine Cancer
pemigatinib
Sensitive: C3 – Early Trials
pemigatinib
Sensitive
:
C3
pemigatinib
Sensitive: C3 – Early Trials
pemigatinib
Sensitive
:
C3
FGFR mutation
Gallbladder Cancer
FGFR mutation
Gallbladder Cancer
pemigatinib
Sensitive: C3 – Early Trials
pemigatinib
Sensitive
:
C3
pemigatinib
Sensitive: C3 – Early Trials
pemigatinib
Sensitive
:
C3
FGFR mutation
Head and Neck Cancer
FGFR mutation
Head and Neck Cancer
pemigatinib
Sensitive: C3 – Early Trials
pemigatinib
Sensitive
:
C3
pemigatinib
Sensitive: C3 – Early Trials
pemigatinib
Sensitive
:
C3
FGFR mutation
Salivary Gland Cancer
FGFR mutation
Salivary Gland Cancer
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
FGFR mutation
Pancreatic Cancer
FGFR mutation
Pancreatic Cancer
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
FGFR mutation
Glioblastoma
FGFR mutation
Glioblastoma
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
FGFR mutation
Breast Cancer
FGFR mutation
Breast Cancer
E7090
Sensitive: D – Preclinical
E7090
Sensitive
:
D
E7090
Sensitive: D – Preclinical
E7090
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login